BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10933749)

  • 1. Effect of acarbose administration on plasma concentrations of zinc and copper in patients with NIDDM.
    Song YM; Chen MD; Sheu WH
    Kaohsiung J Med Sci; 2000 Apr; 16(4):187-91. PubMed ID: 10933749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acarbose, an unduly neglected antidiabetic drug].
    Iványi J; Gyimesi A
    Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
    Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
    Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes.
    Breuer HW
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):421-40. PubMed ID: 14703948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of therapy with metformin on the concentration of certain divalent cations in patients with non-insulin-dependent diabetes mellitus.
    Doşa MD; Hangan LT; Crauciuc E; Galeş C; Nechifor M
    Biol Trace Elem Res; 2011 Jul; 142(1):36-46. PubMed ID: 20567934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N; Burkert A; Haak T
    Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
    Ogawa S; Takeuchi K; Ito S
    Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acarbose reduces the risk of pre-lunch hypoglycemia in elderly people with diabetes eating rice porridge for breakfast.
    Hsieh CJ
    Diabetes Res Clin Pract; 2010 Sep; 89(3):e66-8. PubMed ID: 20619914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.